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TreatmentAbstract Heart failure (HF) is a systemic and multiorgan syndrome with metabolic failure as
fundamental mechanism. As a consequence of its impaired metabolism, other processes are acti-
vated in the failing heart, further exacerbating the progression of HF.
Metabolic agents are a relatively new class of drugs that act through optimisation of cardiac sub-
strate metabolism. Among the metabolic modulators, Trimetazidine (TMZ) and perhexiline are the
only two agents with proven anti-ischaemic effect currently available. However, due to its major
side effects, perhexiline is not yet approved in the US or Europe.
Clinical trials have demonstrated that the adjunct of TMZ to optimal medical therapy improves
symptoms and prognosis of HF without exerting negative hemodynamic effects. Due to its anti-is-
chaemic/anti-anginal effect and excellent tolerability, the modulation of cardiac metabolism with
TMZ represents a promising approach for the treatment of patients with HF.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Egyptian Society of
Cardiology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Contents
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Figure 1 Targets of cardiac metabolic agents. The ﬁgure depicts
the site of action of modulators of cardiac metabolism. Inhibition
of free fatty acid oxidation favours glucose oxidation and
consequently increases the amount of high energy phosphates
produced/mole of oxygen. AA = amino acids; b-Ox = beta-
oxidation; Cpt1 inhibitors = carnitine palmitoyltransferase 1
inhibitors; GLP1 = Glucagon-like peptide-1; PDH= pyruvate
dehydrogenase kinase; TMZ = Trimetazidine.
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Opie L. Lancet 1999;353:768–769 ‘‘The heart is more than a
pump. It is also an organ that needs energy from metabolism.
A metabolic disease, ischaemia, should ideally be treated by
metabolic therapy’’.
Heart failure (HF) is a growing cardiovascular disease
affecting 1–2% of the population in developed countries,1 with
a noteworthy impact in terms of human and economic
resources.2,3 HF is complex syndrome characterised by a con-
tinuous spectrum of changes, ranging from the subtle loss of
normal function to the presence of symptoms refractory to
medial therapy. It may be associated with different changes
in cardiac physiology, including ventricular dilatation, regional
wall motion abnormalities, and decreases in the left ventricular
ejection fraction and other parameters of ventricular function.
Recently, there has been a growing appreciation of the
complex metabolic processes underlying HF pathophysiology
and symptoms.4 As a consequence, HF is currently conceived
as a systemic and multiorgan syndrome with metabolic failure
as basic mechanism. In fact, the failing heart may be deﬁned as
‘‘an engine out of fuel’’.5 Beyond myocardial metabolic failure,
systemic (peripheral) metabolic regulation has been found to
contribute both to major symptoms (muscle weakness, fatigue,
exercise limitation, and dyspnoea) and to disease progression.4
Taking into account these issues, we will review the role of
metabolic modulators, in particular trimetazidine (TMZ), in
HF focusing on their therapeutic implications.
2. Metabolic processes in the normal and failing heart
Fatty acid oxidation represents the major source of energy for
myocardium, up to 80%. Glucose metabolism provides for the
remaining quantity of energy. At rest, the myocardium uses
15–20% of its maximal oxidative capacity6 and adapts the sub-
strate utilisation during increased demands. A net increase in
glucose and lactate uptake has been demonstrated during
low to moderate intensity exercise, without change in free fatty
acid metabolism.7 Glucose utilisation drops during high inten-
sity exercise compared to lower intensity exercise.8 When the
myocardium is stressed beyond the limits of its metabolic
reserve, an aerobic limit is reached. As a consequence, anaero-
bic metabolism begins and ventricular performance declines.9
Therefore, it is not surprising that altered energetics play an
important role in the pathophysiology of the failing heart. In
particular, chronic HF may be conceived as ‘‘a ketosis-prone
state’’, given the evidence that blood ketone bodies are
increased in this syndrome. In fact, blood ketone body and free
fatty acid levels are higher during the fast and also remain
higher after glucose infusion in patients with chronic HF than
controls.10 Also, it has been found11 that blood ketone bodies
are elevated in chronic HF in proportion to the severity of car-
diac dysfunction and neurohormonal activation. A possible
mechanism is augmented supply of free fatty acids for
ketogenesis due to increased stress hormone-related lipolysis.
Increased mobilisation of free fatty acids could augment
ketogenesis.
Other metabolic abnormalities that characterise HF range
from testosterone deﬁciency, insulin resistance and a metabolic
shift favouring catabolism and impairment in skeletal muscle
bulk and function.12 Notably, changes in substrate utilisationto mitochondrial dysfunction lead to ATP deﬁciency and
impaired contractility.13 In fact, other processes implicated in
the progression of HF such as structural remodelling and
oxidative stress are also activated. All these metabolic alter-
ations are deﬁned with the term ‘‘metabolic remodelling’’,
i.e. remodelling of cardiac energy metabolism, which causes
a decrease in energy production and a switch in energy sub-
strate use. Thus, beyond structural remodelling, metabolic
remodelling can contribute to the progression of HF.14,15
Also, given that the myocardium has low ATP levels, it is
not able to effectively sustain its contractile function,16 leading
to a disorder of cardiac contractility and to the progression of
left ventricular remodelling.6 This represents the so-called
‘‘metabolic vicious circle’’.14 However, the exact effects of
metabolic impairment in HF still need to be fully elucidated.
For these reasons, improving cardiac metabolism may be
an appealing approach in HF, with signiﬁcant clinical implica-
tions that go beyond the mere energetic supply.
3. Treatment of HF with metabolic agents
On the basis of the aforementioned evidence, therapeutic
strategies targeted to the metabolic processes have been devel-
oped in the last decades.2 According to the European Society of
Cardiology guidelines,17 the neurohormonal antagonists
(ACE-inhibitors, beta-blockers, mineralocorticoid receptor
antagonists and angiotensin receptor blockers) are used to
modify the progression of systolic dysfunction in chronic HF,
often in combination with a diuretic to relieve symptoms and
signs of congestion. However, despite these pharmacotherapies
can improve clinical symptoms of HF, the prognosis remains
poor.
Conversely, metabolic agents may be particularly efﬁca-
cious, when added to standard therapies, because they act
through optimisation of cardiac substrate metabolism without
exerting negative hemodynamic effects.6 Fig. 1 shows the dif-
ferent mechanisms of action of metabolic modulators.
Table 1 Modulators of cardiac metabolism.
Metabolic eﬀect at pharmacological doses Anti-ischaemic eﬀect Major side eﬀects Marketed
Trimetazidine FFA inhibitor ++++ Gastrointestinal Worldwide
Perhexiline CPI inhibitor +++ Liver toxicity Australia
Etomoxir CPI inhibitor  Left ventricular hypertrophy No
Niacin Uptake inhibitor  Lymphoma Worldwide
Ranolazine None + QT prolongation, Liver toxicity US/Europe
Dichloroacetate Inhibitor of PDH kinase +++ No
CPI = C-kinase potentiated Protein phosphatase-1 Inhibitor; FFA= free fatty acids; PDH= pyruvate dehydrogenase complex.
Metabolic approach to heart failure 179Nicotinic acid (niacin) is a broad-spectrum antiatherogenic
compound involved in the pathway of lipid metabolism.
Beyond its beneﬁcial effects on ischaemic heart disease (i.e.
decreased atherosclerotic lesion progression and increased
lesion regression),18 it can also alter energy metabolism acting
on arterial FFA concentrations and uptake, and b-oxidation.
Ranolazine is an antianginal drug approved in the United
States for the treatment of chronic stable angina, which also
reduces myocardial stunning and infarct size.15 It mainly acts
through a shift in myocardial energymetabolism from fatty acid
b-oxidation towards glucose oxidation, therefore increasing
ATP generation and, ultimately, improving contractile function.
The CPT inhibitor etomoxir was found to protect heart
from fatty acid-induced ischaemic injury independent of
changes in long chain acylcarnitine.19
Dichloroacetate stimulates the mitochondrial pyruvate
dehydrogenase complex by directly inhibiting the activity of
pyruvate dehydrogenase kinase, and it may improve postis-
chaemic recovery of cardiac function.15 Nevertheless, among
the several metabolic modulators, TMZ and perhexiline are
the only two agents with proven anti-ischaemic effect currently
available on the market (Table 1). They both directly inhibit
myocardial fatty acid oxidation and improve regional and glo-
bal myocardial function.20 CPT inhibitor perhexiline is used in
Australia and some parts of Asia for the treatment of chronic
stable angina and has growing evidence of its efﬁcacy in
HF.21,22 However, it is not yet approved in the US or
Europe, due to major side effects such as hepatotoxicity and
peripheral neuropathy.23
4. Efﬁcacy of TMZ in HF
TMZ is an inhibitor of free fatty acid oxidation that shifts car-
diac and muscle metabolism from free fatty acids to glucose
utilisation resulting into a greater production of high-energy
phosphates and into an anti-ischaemic effect.24–27 Since the
early 70s, there has been growing evidence that TMZ lessens
ischaemic injury, and myocardial ischaemia and improves car-
diac function both in animals28–31 and in humans.32–42
In particular, there are consistencies on the efﬁcacy of TMZ
in ischaemic cardiomyopathy across studies. The efﬁcacy of
TMZ added to standard therapy has been found in improving
symptoms (e.g. dyspnoea,37 and ischaemic symptoms43), left
ventricular ejection fraction,36–40,44 cardiac volume,37,44 -
inﬂammation,45 contractility,46 fasting blood glucose and
endothelial function.40,47 Taken all together, these studies sug-
gest that TMZ may be used to improve left ventricular func-
tion and to relieve symptoms in patients with post-ischaemic
HF. A randomised clinical trial39 further demonstrated the
effect of TMZ added to conventional therapy in improvingfunctional class, left ventricular end-systolic volume and ejec-
tion fraction in patients with HF of various origins. As shown
by an international multicentre retrospective cohort study data
on 669 patients with chronic HF,41 the adjunct of TMZ to con-
ventional therapy is effective in reducing mortality and
improves long term survival. A meta-analysis of randomised
controlled trials in HF,48 has conﬁrmed that TMZ ameliorates
cardiac function for ischaemic and non-ischaemic HF, and
reduces mortality, cardiovascular events and hospitalisation.
Another meta-analytic study,49 in chronic HF patients, has
shown that TMZ decreases hospitalisation for cardiac causes
and improves clinical symptoms, cardiac function and left ven-
tricular remodelling.
Finally, TMZ has no deleterious effect on heart rate or
blood pressure.43
5. Mechanisms of action of TMZ
The efﬁcacy of TMZ in improving HF may be mainly
explained considering the effect of the modulation of free fatty
acids metabolism on cardiac function. It acts on the formation
of reactive oxygen species leading to improved reperfusion
mechanical function.50 It has been observed that TMZ coun-
teracts stress-induced atrophy in skeletal muscle myotubes.51
This may explain the effect of TMZ on functional capacity
in cardiovascular patients.35,52,53 The positive action of TMZ
on exercise performance could be ascribed to a cytoprotective
mechanism exerted by TMZ on skeletal muscle integrity. Also,
unpublished data from our group further indicate that TMZ
reduces size loss and cytoskeleton alterations caused by
Tumour Necrosis Factor a, and that TMZ increases glucose
consumption and reduces glycogen content in murine skeletal
muscle myotubes (Ferraro, personal communication).
Also, the effect of TMZ may be mediated through a reduc-
tion of metabolic demand at the level of the peripheral mus-
cles. A study42 has demonstrated TMZ to reduce the whole-
body rate of energy expenditure in patients with HF. Thus,
TMZ could improve symptoms and left ventricular function
in patients with HF through the reduction of whole-body
energy demand.6. Conclusions
Patients with HF have metabolic disturbances that reduce the
ATP production, which also causes a reduction in contractile
reserve. Optimisation of cardiac metabolism should be ideally
obtained with inhibition of FFA oxidation, improvement in
insulin sensitivity and fuelling of the Krebs cycle with amino
acids.
180 G.M.C. Rosano et al.TMZ has been shown to exert a cytoprotective effect. The
inhibition of free fatty acid oxidation with TMZ improves car-
diac metabolism at rest and during stress, therefore ameliorat-
ing symptoms and prognosis in HF patients. Because of its
effectiveness, excellent tolerability, and unique metabolic
mechanisms of action, TMZ represents a promising drug for
the treatment of patients with HF. The effect of a comprehen-
sive metabolic approach to HF should be tested in future clini-
cal trials.
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